Establishing normal reference ranges for PSA change with age in a population-based study: The Krimpen study

Prostate

Volumn 66, Issue 4, 2006, Pages 335-343

  Bosch, J L H R ^a   Tilling, K ^b   Bohnen, A M ^c   Donovan, J L ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Active surveillance; Prostate cancer; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; ASSAY; CALCULATION; DIGITAL RECTAL EXAMINATION; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE; REFERENCE VALUE; TRANSRECTAL ULTRASONOGRAPHY;

AGE FACTORS; AGED; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES;

EID: 33644785202     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20293     Document Type: Article

References (31)

1. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, de Koning HJ. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-878.
2. McGregor M, Hanley JA, Boivin JF, McLean RG. Screening for prostate cancer: Estimating the magnitude of overdetection. CMAJ 1998;159:1368-1372.
3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-990.
4. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361:1122-1128.
5. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. Br Med J 2002;325:740-745.
6. Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 2003;170:1804-1807.
7. Carter HB, Partin AW. Diagnosis and staging of prostate cancer. Chapter 88. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. Campbell's urology, 8th edition. Philadelphia: Saunders; 2002. pp 3055-3079.
8. Blanker MH, Groeneveld FP, Prins A, Bernsen RMD, Bohnen AM, Bosch JLHR. Strong effects of definition and nonresponse bias on prevalence rates of clinical benign prostatic hyperplasia: The Krimpen study of male urogenital tract problems and general health status. BJU Int 2000;85:665-671.
9. Torp-Pedersen S, Juul N, Jakobsen H. Transrectal prostatic ultrasonography. Equipment, normal findings, benign hyperplasia and cancer. Scand J Urol Nephrol Suppl 1988;107:19-25.
10. Blanker MH, Prins J, Bosch JLHR, Schouten BWV, Bernsen RMD, Groeneveld FPMJ, Bohnen AM. Loss to follow-up in a longitudinal study on urogenital tract symptoms in Dutch older men. Urol Int 2005; 75: (in press). DOI: 10.1159/000025924.
11. Yurdakul G, Bangma CH, Blijenberg BG, van Zelst BD, Wildhagen MF, van der Kwast TH, Schröder FH. Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol 2002;42:154-158.
12. Lindsey J. Models for repeated measurements. Oxford: Oxford Science Publications; 1993.
13. Goldstein H. Multilevel statistical models, 2nd edition. London: Edward Arnold; 1995.
14. Tilling K, Sterne JA, Wolfe CD. Multilevel growth curve models with covariate effects: Application to recovery after stroke. Stat Med 2001;20:685-704.
15. Bosch JL, Hop WC, Niemer AQ, Bangma CH, Kirkels WJ, Schröder FH. Parameters of prostate volume and shape in a community-based population of men 55 to 74 years old. J Urol 1994;152:1501-1505.
16. Bosch JL, Hop WC, Bangma CH, Kirkels WJ, Schröder FH. Prostate specific antigen in a community-based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index and symptoms of prostatism. Prostate 1995;27:241-249.
17. Tilling K, Sterne JA, Rudd AG, Glass TA, Wityk RJ, Wolfe CD. A new method for predicting recovery after stroke. Stroke 2001; 32:2867-2873.
18. Woodhouse G. Multilevel modelling applications: A guide for Users of MLn. 1996.
19. StataCorp. Stata Statistical Software: Release 5.0. College Station, Texas: Stata corporation, 1997.
20. Blanker MH, Groeneveld FP, Thomas S, Prins A, Bohnen AM, Bosch JL. Prostate cancer detection in older men with and without lower urinary tract symptoms: A population-based study. JAGS 2003;51:1041-1042.
21. Rietbergen JB, Hoedemaker RF, BoekenKruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: Characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999;161:1192-1198.
22. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
23. Anderson JR, Strickland D, Corbin D, Byrnes J, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. Urology 1995;46:54-57.
24. Schröder FH, de Vries SH, Bangma CH. Watchfull waiting in prostate cancer: Review and policy proposals. BJU Int 2003;92:851-859.
25. Carter HB, Morrell CH, Pearson JD, Brant LJ, Plato CC, Metter EJ, Chan DW, Fozard JL, Walsh PC. Estimation of prostatic growth using serial prostate-specific antigen measurement in men with and without prostate disease. Cancer Res 1992; 52:3323-3328.
26. Raaijmakers R, Wildhagen MF, Roobol MJ, de Vries SH, Schroder FH. PSA-verandering in een screeningspopulatie. Ned Tijdschr Geneesk 2004;148:111 (abstract).
27. Stephenson AJ, Aprikian AG, Souhami L, Behlouli H, Jacobson AI, Begin LR, Tanguay S. Utility of PSA doubling time in follow-up of untreated patients with localised prostate cancer. Urology 2002;59:652-656.
28. McLaren DB, McKenzie M, Duncan G, Pickles T. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behaviour in patients with early untreated prostate carcinoma. Cancer 1998;82:342-348.
29. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, Fleshner N, Bunting P, Kapusta L, Hruby G. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 2001;50:615-620.
30. Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, Carroll PR. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: Results from CaPSURE. J Urol 2003;170:1804-1807.
31. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, Frankel S, Neal D, Hamdy F. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Br Med J 2002;325:766-770.